Esperion (ESPR) Director Seth H. Z. Fischer Sells Shares in Merger

What Happened

• Seth H. Z. Fischer, a director of Esperion Therapeutics, disposed of a total of 238,523 shares (and share equivalents) on July 13, 2026. Under the merger agreement, each share was converted into $3.16 in cash (per-share cash consideration) and one contingent value right (CVR). The cash proceeds from these dispositions total approximately $753,732.68 (rounded to $753,733). The dispositions were not open-market sales but conversions/settlements effected at the merger's Effective Time.

Key Details

• Transaction date: July 13, 2026 (Effective Time of the merger).
• Total disposed: 238,523 shares/equivalents (details reported as four dispositions: 141,023; 21,000 (derivative); 32,500 (derivative); 44,000 (derivative)).
• Per-share cash consideration: $3.16; total cash received ≈ $753,732.68 (rounded $753,733) plus one CVR per share (contingent payments tied to milestone achievement).
• Includes 79,873 RSUs that vested and were converted into cash + CVRs (per footnote).
• In‑the‑money stock options were canceled and converted into cash payments plus CVRs for the excess over exercise price (per footnote).
• Transaction type/code: Disposition to issuer (D) under the Agreement and Plan of Merger.
• Shares owned after transaction: Common stock shares were canceled at the Effective Time; the filing indicates conversion to cash and CVRs (common shares are no longer outstanding).
• Filing timely: Reported on the same day (filed July 13, 2026).
• Exhibit listed: Exhibit 24 — Power of Attorney.

Context

• These were merger-related conversions (not market sales). The insider received cash and CVRs under the merger terms; CVRs are contingent rights that may pay additional cash if specified milestones are met in the future. This is a routine corporate action tied to the change of control rather than a discretionary sale by the director.